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Summary A fusion protein consisting of the humanised Fab fragment of the anti CEA MAb BW 431 and the
human ,B-glucuronidase was expressed in BHK cells. Functional testing revealed that the specificity and avidity
of the humanised V region was similar to the original murine MAb BW 431. Furthermore, the enzymatic
activity, pH sensitivity and stability of the human P-glucuronidase in the fusion protein was comparable to the
activity of recombinant human P-glucuronidase. Using anti-idiotype affinity chromatography, two molecules of
a molecular weight of 125 kDa or 250 kDa could be visualised under nonreducing conditions in SDS-PAGE.
Reducing conditions revealed a 25 kDa light and 100 kDa heavy chain. Due to its suitable biological
characteristics this fusion protein might be an appropriate molecule allowing a site specific antibody directed
enzyme prodrug therapy (ADEPT) in vivo.
Currently, the treatment of non-disseminated solid tumours
is performed by surgery and irradiation. Both methods can
be considered to be relatively tumour selective, without signi-
ficantly harming the rest of the body. If however the tumour
has disseminated to various organ sites, the metastases can
be treated by chemo- or hormone therapy only. Chemotherapy
has considerable side effects and a minor influence on
patients' survival due to the lack of specificity of action or
the induction of resistance. Hormone therapy alone has a
limited tumour spectrum.
To overcome these obvious limitations of today's treat-
ment modalities, we tailored a fusion gene consisting of the
VH and CHI Exons of a humanised MAb and the human
P-glucuronidase cDNA (Lorenz et al., 1991). The product
encoded by the fusion gene might be suitable for performing
an antibody directed enzyme prodrug therapy (ADEPT). The
concept of ADEPT as developed by Philpott et al. (1973a,b;
1974) and reemphasised by Bagshawe (1987) and Bagshawe
et al. (1988) assumes that an antibody enzyme conjugate after
selective localisation at the tumour target site, and its
clearance from normal tissues, activates a nontoxic low
molecular weight prodrug to a highly toxic drug in the
tumour by enzymatic catalysis.
The therapeutic success of this approach depends on
several factors:
(a) The stability of the prodrug in vivo.
(b) The difference in toxicity between prodrug and drug.
(c) The molar toxicity of the drug.
(d) The pharmacokinetics of the prodrug.
(e) The tumour selectivity of the antibody enzyme con-
jugate.
(f) The turnover rate of the enzyme used in the conjugate.
(g) The molecular weight and pharmacokinetic of the
antibody enzyme conjugate.
(h) The percolation and retention of the antibody enzyme
conjugate at the tumour site and its elimination
kinetics from normal tissues.
(i) The concentration of free unconjugated endogenous
enzyme.
(j) The immunogenicity of the antibody enzyme con-
jugate.
Despite the obvious complexity of the system, a first clinical
trial with a F(ab')2 fragment of a murine anti CEA MAb
chemically linked to carboxypeptidase G2 (CPG2) from
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Pseudomonas origin combined with a para-N (mono-2-chloro-
ethyl monomesyl) amino benzoyl glutamic acid prodrug was
performed (Bagshawe, 1991). Five patients with advanced
colorectal carcinomas were treated. In two out of five
patients, regression of CEA expressing metastases was
observed in addition to minor responses in three out of five
patients. Treatment became inefficient due to the fast activa-
tion of a neutralising anti CPG2 immune response. This trial
shows that the ADEPT concept works in the patient, but has
to be optimised to obtain better therapeutic effects.
Our approach to the ADEPT concept is based on the
availability of the high avidity anti CEA MAb BW 431
(Bosslet et al., 1988), its CDR-grafted (Jones et al., 1986;
Riechmann et al., 1988) humanised version (Giissow &
Seemann, 1991) and the cloned cDNA for human placental
P-glucuronidase (Oshima et al., 1987), a lysomal endogenous
enzyme (Brot et al., 1978). Out of these human building
blocks a fusion gene was constructed (Lorenz et al., 1991).
This construction was performed in analogy to the original
work of Neuberger's group (Neuberger et al., 1984; Williams
& Neuberger, 1986) who showed that a fusion protein
between a mouse Fab and nuclease or polymerase could be
functionally expressed. In the present paper the molecular
and functional characteristics of a fully humanised/human
fusion protein expressed in BHK cells will be reported.
Materials and methods
Recombinant DNA-techniques
Construction and cloning of the fusion gene was done by
standard recombinant DNA techniques (Sambrook et al.,
1989) as described by Lorenz et al. (1991b).
DNA-transfection
BHK cells were transfected with plasmid DNA by Ca-
phosphate coprecipitation (Graham & van der Eb, 1973).
Supernatants of BHK cells growing in selection medium were
tested for functionally active fusion protein using the fusion
protein activity assay described below.
Fusion protein activity assay
Polystyrol U-bottom microtiter plates were coated with 0.1-
0.5 yg CEA or mucin. After blocking with 1% casein in PBS,
pH 7.2, 50 il of BHK transfectoma supernatant were added
and removed after 30' of incubation at RT. After extensive
washing of the plates, 50pl of a 2.5 mM 4-methylumbelliferyl-
P-D-glucuronide solution in 200mM sodium acetate buffer,
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pH 5, was added and incubated for 2 h at 37°C. The reaction
was stopped using 0.2 M glycine + 0.2% SDS, pH 11.1. Fluo-
rogenic units (FU) were determined as described by Glaser
and Sly (1973).
Avidity determination
Avidity of fusion protein to purified CEA was determined
according to Tipton et al. (1990). The avidity to cell bound
CEA was measured as described by Bosslet et al. (1988).
Histochemical and immunohistochemical tissue specificity
Transfectoma supernatants containing fusion protein were
added to cryopreserved tissue sections from various human
tissues for 30' at RT. After washing the selectively bound
fusion protein was histochemically detected via its enzymatic
catalysis resulting in a red unsoluble stain as described by
Murray et al. (1989) or visualised immunohistochemically
using an alkaline phosphatase labelled goat anti B-glucuro-
nidase antibody.
Purification and analysis offusion protein
BHK transfectoma supernatants containing the fusion pro-
tein were purified by anti-idiotype affinity chromatography
(Bosslet et al., 1991). Adsorption was performed at pH 7.2,
elution was done at pH 4. Samples of the elution peak were
analysed by SDS-PAGE under reducing or nonreducing con-
ditions followed by silverstaining (Poehling & Neuhoff, 1981)
or Western blotting (Towbin & Gordon, 1979).
Results
Short description ofthe DNA constructs
A fusion gene was constructed consisting of the human IgG
promoter region and signal peptide exon, the humanised
version of the rearranged VH gene of MAb BW 431, the CHI
exon of human IgG3, one hinge exon derived from human
IgG3, a synthetic linker peptide and the cDNA coding for the
mature human P-glucuronidase. This construct was inserted
via its HindIII and SalI restriction sites in the pAB-vector
(Chart 1) (Zettlmeissl et al., 1987).
A second pAB-vector containing the gene for the humanis-
ed light chain of MAb BW 431 is depicted in chart 2. The
light chain gene contains the humanised V-gene of the L-
chain with IgG promoter region and signal exon and the
human C-kappa gene. These two vectors were cotransfected
into BHK cells with the plasmid pRMH 140, carrying a
neomycin resistance gene (Hudziak et al., 1982) and the
plasmid pSVdhfr (Subramani et al., 1981) carrying the di-
hydrofolate reductase gene allowing positive selection with
methotrexate (Wirth et al., 1988).
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Detection offSusionprotein secreting transfectomas
BHK cells were transfected by Ca-phosphate co-precipitation
(Graham & van der Eb, 1973) using the four independent
plasmids outlined above. Supernatants from transfectoma
clones grown in selection medium containing G418 and
methotrexate were evaluated in the fusion protein activity
assay (see Materials and methods). Out of 97 transfectomas
investigated eight transfectomas secreted detectable amounts
of molecules with CEA binding potential and P-glucuroni-
dase activity.
Purification and analysis offusion protein
Supernatants from BHK transfectoma cells were processed
through an anti-idiotype affinity column as described in
Materials and methods. Samples collected from the elution
peak at pH 4 were analysed by SDS-PAGE under reducing
and nonreducing conditions followed by silverstaining. The
SDS-PAGES presented in Figure 1 reveal two bands with an
apparent MW of
- 100 kDa and t 25 kDa under reducing
conditions and two major bands of a MW of ; 250 kDa
and A 125 kDa under nonreducing conditions. A minor
band of a MW of 200 kDa was detected as well.
Western blotting of reduced SDS-PAGE using a horse
radish peroxidase labelled (HRP) goat anti human K anti-
serum as a detection system revealed a 25 kDa band. Under
nonreducing conditions both a 125 kDa and a 250 kDa band
were visualised. A 100 kDa band was detected under reduc-
ing conditions if a HRP labelled goat anti human P-glucuro-
nidase antiserum was used for immunostaining. Nonreducing
conditions revealed two major bands at 125 and 250kDa
after staining with the HRP labelled goat anti human ,B-
glucuronidase antiserum. Furthermore, TSK 3000 gel chro-
matography of native eluate revealed a single major peak of
P-glucuronidase activity at a molecular weight position of
approximately 250 kDa (data not shown).
Avidity determination ofthepurifiedfusion protein
The strength of binding of the purified native fusion protein
to purified CEA as well as to cell-associated CEA was deter-
mined in comparison to MAb BW 431 or its humanised
version. The association constants as determined for the
three molecules by two independent methods were in the
range of 101Imol' and did not show significant differences
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SDS - PAGE offusion protein hu 431 Gluc
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TableI Comparison oftheavidity ofthe murine MAb BW 431 with its
CDR-grafted humanised version and the fusion protein
ka ( x 10101 (Mol) l
mu BW 431 3.0-4.7a 3.7b
hu BW 431 1.0-2.2a 1.4b
hu 431 P-gluc 1.3-2.Oa 2.5b
aTipton et al. (1990); bBosslet et al. (1988).
-97.4 97.4
-
23 - -68
A B C A
7.5-15% 7.5%
acrylamide acrylamide
Figure 1 Photograph showing two silverstained SDS-PAGES.
Lanes A represents molecular weight markers. Lane B shows the
purified fusion protein under reducing conditions, Lane C under
nonreducing conditions.
Histochemical and immunohistochemical evaluation ofthe
tissue specificity
The avidity evaluation proved that the binding capacity of
the fusion protein to purified CEA or CEA bearing cell lines
was unchanged compared to the original MAb BW 431 or its
humanised version. To further investigate the properties of
the fusion protein's binding region we evaluated its histo-
chemical and immunohistochemical specificity on cryopre-
served human tissue sections. The data collected from several
independent experiments are presented in Table II. Histo-
chemical investigations using naphtyl P-glucuronide com-
bined with hexazotised pararosaniline as substrate for the
,-glucuronidase (Murray et al., 1989) revealed that the fusion
protein binds to all colon and stomach carcinomas and is
enzymatically active. Normal lung and brain are not stained,
as expected. Normal liver and kidney are weakly stained due
to endogenous lysosomal ,-glucuronidase also detectable in
the MAb BW 431 negative control (lanes 1 and 2). Further-
more the immunohistochemical specificity using an AP-labell-
ed goat anti human ,-glucuronidase antibody or an AP-
labelled goat anti mouse Ig antibody showed an identical
staining reaction. The colon and stomach carcinomas were
positive, whereas the normal tissues like lung, liver, kidney
and brain were negative as reported for MAb BW 431. Again
a weak reaction due to binding of the anti P-glucuronidase
antibody to endogenous P-glucuronidase was observed (lanes
3 and 4). These data clearly demonstrate that the fusion
protein has a specificity similar or identical to that of the
original MAb BW 431.
Influence ofpH on the catalytic rate ofthefusion protein
After the purification of the fusion protein and the deter-
mination of its binding potential to purified CEA the turn-
over rate at various pH values was determined. Figure 2
shows the pH dependence of the fusion protein bound to
solid phase attached CEA as revealed by the fusion protein
activity assay.
The maximal catalytic rate was observed at pH 4.5. At
pH 7.4, the pH in normal tissues, the catalytic rate is about
10% of the optimal value. At pH 7.0, a pH reported for solid
tumours (Tannock & Ratin, 1989) the catalytic rate is about
20% of the maximal activity. After adjustment of pH from
7.4 to 4.5 the fusion protein revealed its full catalytic poten-
tial arguing for its stability (data not shown).
Determination ofthe turnover rate ofthefusion protein
With the help of the fusion protein activity assay, a linear
correlation between incubation time, fusion protein concen-
tration and liberated fluorogenic units (FU) could be demon-
strated (Figure 3). One thousand FU corresponded to 0.14 j.g
methylumbelliferone (MU), the liberated fluorogenic label.
Based on this correlation the turnover rate of the fusion
protein was determined. At pH 7.0, 1 Mol of CEA bound
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Figure 2 Fluorogenic units (FU) are plotted against the pH
value. Values obtained with 500 ng , 83 ng ---- or 16 ng ......
of fusion protein are presented and show a similar type of curve.
konz. ; 1:6 ----; 1:32 .*---. Incubation 2h of 37C.
Table II Histochemical and immunohistochemical evaluation ofthe tissue specificity ofthe fusion proteincompared
to MAb BW 431
Immunohistochemical substrate reaction using
Histochemical substrate reaction using AP-labelled
naphtyl P-glucuronide and hexazotised
Tissues investigated pararosaniline Goat antiP-glucuronide Goat anti mouse Ig
antibody antibody
fusion protein MAb BW 431 fusion protein MAb BW 431
Carcinomas positive/tested positive/tested positive/tested positive/tested
Colon Cas 7/7 0/7 7 /7 7/7
Stomach Cas 4/4 0/4 4/4 4/4
Normal tissues
Lung 0/3 0/3 0/3 0/3
Liver 4a/4 4a/4 4a/4 0 /4
Kidney 2'/2 2a/2 2a/2 0 /2
Brain 0/2 0/2 0/2 0/2
aEndogenous intralysosomal P-glucuronidase detectable in sections without fusion protein also.
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fusion protein cleaves ; 12,000 moles of methylumbelliferyl
P-glucuronide, the synthetic prodrug in 1 h at 37°C.
Similar turnover rates were observed using a prodrug bas-
ed on daunomycin linked via a urethane nitrophenyl spacer
to 13-glucuronic acid (manuscript in preparation).
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Figure 3 Fluorogenic units (FU) are plotted against the incuba-
tion time at 12.5 ng , 2.5 ng ---- or 0.25 ng .*.-of fusion
protein. A linear time-activity relationship was found at all three
fusion protein concentrations.
a
Discussion
This study demonstrated that the molecular construct con-
sisting of the binding region of the humanised anti CEA
MAb 431 and the human endogenous lysosomal enzyme
P-glucuronidase could be expressed and purified to homo-
geneity as a highly effective fusion protein. Using the 'fusion
protein activity assay' we were able to detect eight BHK
transfectomas secreting significant amounts of fusion protein
that bind to CEA and catalyse the cleavage of the 4-methyl-
umbelliferyl P-glucuronide prodrug to 4-methylumbelliferone
and glucuronic acid due to the fusion protein's ,-glucu-
ronidase activity. From transfectoma supernatants two
molecules could be isolated using anti-idiotype affinity
chromatography. Under denaturing conditions, one molecule
represented a monovalent protein and the other consisted of
a bivalent protein as revealed by our SDS-PAGES and
Western blotting data (Figure 1). A schematic diagram of the
two molecules is given in Figure 4a. The monovalent mole-
cule (Figure 4b) of a MW of 125 kDa contains the light
chain of the humanised MAb BW 431 consisting of the VL
and CL domains covalently linked by an interchain disulphide
bond to the humanised heavy chain. The humanised heavy
chain is built up by the VH and CHl domain of the humanis-
ed MAb BW 431 the N-terminal part of the human IgG3
hinge region, a linker peptide and the human P-glucuro-
nidase. In this monovalent molecule the two hinge region
cysteins form an intrachain disulfide bond. If the hinge
region cysteins form two interchain disulfide bonds a bivalent
fusion protein arises (Figure 4c) which can be isolated from
transfectoma supernatants at a similar amount as the mono-
valent fusion protein (Figure 4c). Under native conditions the
two molecular forms exist as bivalent molecules (Figure 4d)
as shown by gel chromatography under non denaturing con-
ditions.
Furthermore, the mild elution conditions applicable to the
anti-idiotype affinity chromatography resulted in the isolation
of a protein fraction with satisfying biochemical properties.
b
VH CH1 hll
Gluc
VL CL
fusion protein
Figure 4 A schematic diagram of the molecular species of fusion protein secreted from transfectoma supernatant is shown.
a, Fusion protein molecules found under denaturing conditions after isolation using anti-idiotype affinity chromatography.
b, Diagram of the fusion protein monomer showing the building blocks of the construct. c, Diagram of the fusion protein dimer
with covalent linkage by two interheavy chain disulfide bonds. d, Diagram of two fusion protein dimers with and without
interheavy chain disulfide bonds. Both molecules are found under native conditions after isolation using anti-idiotype affinity
chromatography.
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Avidity to CEA was found by two independent methods to
be in the range of 101 I Mol', a figure similar to the avidity
of the murine MAb BW 431 or its humanised version (Table
I). Since the molecular forms of the fusion protein as reveal-
ed under denaturing conditions are associated in the native
state forming molecules with two identical binding sites, the
avidity measurements refer to the binding strength of biva-
lent molecules. In addition, the histochemical and immuno-
histochemical tissue specificity of the fusion protein was not
distinguishable from that of the murine MAb BW 431 (Table
II). Not only the binding portion of the fusion protein was
functionally active, but also the enzyme moiety showed a
catalytic activity and pH profile similar to human P-glucu-
ronidase (Brot et al., 1978). Despite the fact that the catalytic
optimum of the fusion protein is at pH 4.5 and the turnover
rate at pH 7.0, a pH value assumed for human solid tumours
(Tannock & Ratin, 1989), is about 20% of the optimal rate it
still seems to be high enough to fulfill the assumptions made
in the ADEPT concept. Due to its fully human or humanised
building blocks, the fusion protein should have a low
immunogenicity in humans, if at all. This characteristic
should allow the long term application of this molecule in
humans and distinguishes this construct from xenogeneic
mouse antibody - bacterial enzyme conjugates which were
reported to elicit a fast neutralising antibody response in the
patient (Bagshawe et al., 1991). Before the fusion protein can
be considered for clinical evaluation, its pharmacodynamic
(Natowicz et al., 1979) in relation to the carbohydrate con-
tent (Stahl et al., 1976) and therapeutic effects combined with
appropriately designed prodrugs (Stella et al., 1985) must be
studied in further preclinical model systems. Prodrug systems
which are investigated presently are glucuronides of dauno-
mycin and adriamycin. To our knowledge, this is the first
report, describing a functionally active fusion protein, con-
sisting of a humanised tumour selective binding portion and
a human lysosomal enzyme with potential applicability for a
more selective tumour therapy.
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